Morgan Stanley has identified three major breakthroughs in the biotechnology sector that could create significant investment opportunities. These advances primarily concern Alzheimer’s disease, gene editing, and artificial intelligence applied to healthcare. The American bank highlights these three areas as potentially capable of shaping investor returns in the coming years. This analysis is part of a broader trend where financial institutions are taking a closer interest in biotech sector innovations.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
